368 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
AGN Allergan plc. $184.29 $62.56B N/A
Article Searches
Allergan (AGN) Enters Strategic Alliance With Editas Medicine (EDIT) - Slideshow http://seekingalpha.com/article/4055538-allergan-agn-enters-strategic-alliance-editas-medicine-edit-slideshow?source=feed_sector_healthcare Mar 15, 2017 - The following slide deck was published by Allergan plc in conjunction with this event.
Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise http://www.zacks.com/stock/news/252545/acordas-four-ampyra-patents-upheld-by-ptab-shares-rise?cid=CS-ZC-FT-252545 Mar 13, 2017 - U.S. Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld four patents of Acorda's key growth driver, Ampyra.
Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction http://www.zacks.com/stock/news/252531/aerie-resubmits-rhopressa-nda-roclatan-gains-traction?cid=CS-ZC-FT-252531 Mar 13, 2017 - Aerie Pharmaceuticals is a development-stage company focused on the development and commercialization of eye disease therapies, including glaucoma and other eye-diseases.
Why Amgen (AMGN) Stock Rallied After Q4 Earnings Release? http://www.zacks.com/stock/news/252447/why-amgen-amgn-stock-rallied-after-q4-earnings-release?cid=CS-ZC-FT-252447 Mar 10, 2017 - Biotech major, Amgen, Inc.'s (AMGN) shares have risen 12.1% since it reported better-than-expected fourth quarter results on Feb 2.
Allergan's (AGN) Vraylar sNDA Accepted for Review by FDA http://www.zacks.com/stock/news/252294/allergans-agn-vraylar-snda-accepted-for-review-by-fda?cid=CS-ZC-FT-252294 Mar 09, 2017 - Allergan plc (AGN) announced that its supplemental New Drug Application (sNDA) for its schizophrenia capsules Vraylar has been accepted for review by the FDA.
Aerie (AERI) Q4 Loss Widens, Rhopressa NDA Resubmitted http://www.zacks.com/stock/news/252134/aerie-aeri-q4-loss-widens-rhopressa-nda-resubmitted?cid=CS-ZC-FT-252134 Mar 08, 2017 - Aerie Pharmaceuticals, Inc. (AERI) posted fourth-quarter 2016 loss of 87 cents per share (including stock-based compensation), wider than both the Zacks Consensus Estimate of a loss of 65 cents
Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs http://www.zacks.com/stock/news/252108/trump-tweet-on-drug-pricing-hits-biotech-and-pharma-etfs?cid=CS-ZC-FT-252108 Mar 08, 2017 - President Donald Trump March 7 tweet on increasing competition and lowering drug prices sent fresh shockwaves across the industry.
Pharma Industry Outlook - February/March 2017 http://www.zacks.com/commentary/104804/pharma-industry-outlook-february-march-2017?cid=CS-ZC--104804 Feb 27, 2017 - Pharma Industry Outlook - February/March 2017
Markets Climb Amid Solid Q4 Earnings http://www.zacks.com/stock/news/249222/markets-climb-amid-solid-q4-earnings?cid=CS-ZC-FT-249222 Feb 13, 2017 - Market futures are very positive this morning, and continue to climb 20 minutes before the opening bell sounds.
Allergan Plc (AGN) Brenton L. Saunders on Q2 2016 Results - Earnings Call Transcript http://seekingalpha.com/article/3997329-allergan-plc-agn-brenton-l-saunders-q2-2016-results-earnings-call-transcript?source=feed_all_articles Aug 08, 2016 - Allergan Plc (NYSE:AGN)Q2 2016 Earnings CallAugust 08, 2016 8:30 am ETExecutivesLisa M. DeFrancesco - Vice President-Investor RelationsBrenton L. Saunders - President, Chief Executive Officer & Direct

Pages: 1...293031323334353637

<<<Page 34>